In June 2021, the world was informed about a new drug for Alzheimer's disease approved
by the FDA. Aducanumab (BIIB037, ADU), being a monoclonal antibody IgG1, is the newest …

Alzheimer's disease (AD) is the most devastating neurodegenerative disorder affecting the
elderly. The exact pathology of AD is not yet fully understood and several hallmarks such as …

In this paper, we develop a new mathematical model based on the Atangana Baleanu
Caputo (ABC) derivative to investigate meningitis dynamics. We explain why fractional …

With rapid aging of the population worldwide, the number of people with dementia is
dramatically increasing. Some studies have emphasized that metabolic syndrome, which …

Monoamine oxidase is a flavin enzyme that catalyzes the oxidation of monoamine
neurotransmitters in the brain. Various toxic by-products, aldehydes and hydrogen peroxide …

Dementia is a growing public health concern, with an estimated prevalence of 57 million
adults worldwide. Alzheimer's disease (AD) accounts for 60–80% of the cases. Clinical trials …

Ethnopharmacological relevance Stroke is one of the leading causes of death and disability.
The only FDA-approved therapy for treating stroke is tissue plasminogen activator (tPA) …

Alzheimer's disease (AD) is the most common cause of dementia in elderly people;
currently, there is no efficient treatment. Considering the increase in life expectancy …

Abstract Alzheimer's disease (AD), which is characterized by extracellular accumulation of
amyloid-beta peptide and intracellular aggregation of hyperphosphorylated tau, is the most …

Alzheimer's disease (AD) stands as a formidable neurodegenerative ailment that poses a
substantial threat to the elderly population, with no known curative or disease-slowing drugs …